Literature DB >> 9622381

A new genetic variant in the Sp1 binding cis-element of cholecystokinin gene promoter region and relationship to alcoholism.

S Harada1, T Okubo, M Tsutsumi, S Takase, T Muramatsu.   

Abstract

Neuropeptide cholecystokinin (CCK) and the CCK receptors in the central nervous system mediate actions on increasing firings, anxiety, and nociceptions. Furthermore, CCK modulates the release of dopamine and dopamine-related behaviors in the mesolimbic pathway. In our study, genetic variation in the promoter and coding regions of the prepro-CCK gene were analyzed among 66 Japanese, 66 American Whites, 54 Chinese, and 41 Colombian natives. Two nucleotide sequence variants were found: a frequent mutation at nucleotide position -45 C to T involved in core sequence of Sp1 binding cis-element of the promoter region, and a C to T substitution at the 1662 position in intron 2. Analysis for the segregation study in 10 families of twins confirmed codominant heredity of two alleles. Distribution of genotypes and gene frequencies of 66 controls and 108 alcoholics in Japan presented that allelic variant T type in alcoholics was found in higher frequencies than that of controls, and distribution of these genotypes was significantly different between the both groups.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622381     DOI: 10.1111/acer.1998.22.s3_part1.93s

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  2 in total

1.  Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations.

Authors:  Jennifer G Goldman; Darcy Marr; Lili Zhou; Bichun Ouyang; Sue E Leurgans; Elizabeth Berry-Kravis; Christopher G Goetz
Journal:  Mov Disord       Date:  2011-04-19       Impact factor: 10.338

2.  Genetic analysis of a population heavy drinking phenotype identifies risk variants in whites.

Authors:  Ajna Hamidovic; Robert J Goodloe; Taylor R Young; Mindi A Styn; Kenneth J Mukamal; Helene Choquet; Jay L Kasberger; Sarah G Buxbaum; George J Papanicolaou; Wendy White; Kelly Volcik; Bonnie Spring; Brian Hitsman; Daniel Levy; Eric Jorgenson
Journal:  J Clin Psychopharmacol       Date:  2013-04       Impact factor: 3.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.